These benefits, along with a rise in preventive healthcare, drive the U.S. supplements market for CoQ10.

Methanol, a key chemical intermediary, finds extensive use in the production of formaldehyde, acetic acid and other chemicals, with formaldehyde accounting for more than one-third of all methanol demand. Changing demand patterns have witnessed stagnant growth of methanol consumption in

Allos Therapeutics has reported positive interim response and safety data from the company's pivotal Phase II Propel trial of PDX in patients with relapsed or refractory peripheral T-cell lymphoma.

InSight Health Services has appointed Bernie O'Rourke to the position of executive vice president and COO, effective May 16, 2008.

GE Healthcare IT, a division of General Electric Company, has signed a partnership agreement with M Modal, a provider of advanced speech understanding solutions, to deliver the next generation of radiology reporting technology.

Debiopharm Group has signed a license agreement with its long-term European pharmaceutical partner, for the marketing of Salvacyl/Moapar three-month formulation.

Protox Therapeutics has announced the enrolment and successful dosing of the first patient in a Phase II clinical trial evaluating PRX302 to treat benign prostatic hyperplasia, or enlarged prostate, a common and bothersome urological condition that affects over one million

QMed, a developer of healthcare information systems, has announced that it will shut down its operations in June 2008.

Arpida has announced that the FDA has accepted for review the new drug application for intravenous iclaprim in the treatment of complicated skin and skin structure infections.

Lpath has announced that the FDA, after review of the company's April 2008 investigational new drug submittal, has allowed Lpath to administer iSONEP to patients suffering from exudative age-related macular degeneration in a Phase I clinical trial.

Wyeth Pharmaceuticals has announced that Pristiq, a new serotonin-norepinephrine reuptake inhibitor approved to treat adult patients with major depressive disorder, is now available in US retail pharmacies.

Abbott has launched the StarClose SE Vascular Closure System, a next-generation vessel closure device engineered to enable fast, safe and secure closure of the femoral artery access site following a catheterization procedure. StarClose SE is available in the US and

Molecular diagnostics company Asuragen has announced the CE-mark and European launch of RNARetain Pre-Analytical RNA Stabilization Solution, the company's clinically validated and RNA stabilization solution.

Advanced Medical Optics has received the FDA approval for the iFS Advanced Femtosecond Laser.

St Jude Medical has received the FDA clearance and European CE Mark approval for new delivery tools designed to give physicians greater control and precision when placing cardiac pacing leads in heart anatomy.

Albireo, a Swedish biotechnology company focusing on the development of therapeutics for gastrointestinal diseases, has appointed Hans Graffner, as chief medical officer.

Sanofi-Aventis has announced that findings from the landmark Athena study showed that Multaq, a potential therapy for the treatment of atrial fibrillation or atrial flutter, decreased the risk of cardiovascular hospitalizations or death from any cause by a statistically significant

digiMedical Solutions has signed a non-binding letter of intent with Guardian Health Systems, a Texas-based health services company.

Transdel Pharmaceuticals has announced the closing of a $4 million private placement of its common stock and warrants.

Biotech firm Antisoma has entered into an agreement to acquire US-based oncology company Xanthus Pharmaceuticals, in an all-share deal valued at GBP26.8 million.